Genmab has shared the first data on rinatabart sesutecan (Rina-S) in advanced endome | Genmab has shared the first data on ...

RTX carries a strong balance sheet with a BBB+ credit rating from S&P. This is supported by $5.2 billion in cash on hand, and ...

Results of the trial, which evaluated the efficacy and safety of mirvetuximab soravtansine-gynx (Elahere, AbbVie), were presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

AbbVie's Elahere has been shown to reduce the risk of death in patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer by a third, reinforcing its blockbuster ...

Toon Van Gorp, MD, PhD, discusses the rationale behind and the findings from the phase 3 MIRASOL trial of mirvetuximab soravtansine in patients with folate receptor α–positive, platinum-resistant ...

Solid results were also seen in the neuroscience and oncology segments, with Elahere standing out by bringing in $179 million in global revenue. A major driver of this success was the positive ...

The company also saw solid performance in neuroscience and oncology, with Elahere generating $179 million globally, boosted by favorable results from the MIRASOL trial, which showed it ...

Upcoming data readouts for multiple drugs, including Emraclidine, Elahere, and Tavapadon, are anticipated by the end of 2024 or early 2025. The company’s strategic acquisitions, such as ...

The ImmunoGen deal's star is the ovarian cancer drug Elahere, which had sales of $479 million in 2024. AbbVie is in the process of expanding its use cases significantly to boost sales ...